| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2023 ( Subtotal = $42,412,302 ) (Continued on the next page) |
| | 2023 | 2023 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | R01CA269285 | Cyclin C-CDK8/19 kinases in development and in cancer | 000 | 2 | NIH | 2/28/2023 | $515,451 |
| | 2023 | 2023 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | R01CA213404 | Polyploidy, Aneuploidy and Genome Stability | 001 | 25 | NIH | 3/15/2023 | $52,865 |
| | 2023 | 2023 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | R01HL052725 | Molecular Pathogenesis of Fanconi Anemia | 000 | 28 | NIH | 1/19/2023 | $387,626 |
| | 2023 | 2023 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | R00DK123321 | Mechanistic characterization of the anti-inflammatory function of thermogenic fat for the treatment of metabolic disorders | 000 | 4 | NIH | 2/16/2023 | $249,000 |
| | 2023 | 2023 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | R00CA245899 | Deep clinical trajectory modeling to optimize accrual to cancer clinical trials | 000 | 4 | NIH | 2/7/2023 | $248,999 |
| | 2023 | 2023 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | P30CA006516 | Dana-Farber/Harvard Cancer Center | 000 | 58 | NIH | 1/25/2023 | $12,713,161 |
| | 2023 | 2023 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | K00AG078230 | Effects of Extracellular Mechanics on Mechanosensory and Central Neuron Function | 000 | 4 | NIH | 1/5/2023 | $82,620 |
| | 2023 | 2023 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | R01CA265928 | A precision tumor neoantigen identification pipeline for cytotoxic T-lymphocyte-based cancer immunotherapies | 000 | 2 | NIH | 3/8/2023 | $660,767 |
| | 2023 | 2023 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | R01LM013352 | Statistical Methods and Validation Analyses for the Integration of External Data in Clinical Trials | 000 | 3 | NIH | 12/27/2022 | $376,182 |
| | 2023 | 2023 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | R01AI158488 | CDK4/6 inhibition during CD8 T cell priming potentiates memory formation in mice and humans | 000 | 3 | NIH | 3/2/2023 | $445,000 |
| | 2023 | 2023 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | K08CA252639 | Can a subset of patients with HER2+ metastatic breast cancer be cured? | 000 | 3 | NIH | 3/8/2023 | $258,561 |
| | 2023 | 2023 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | R37CA255245 | Targeting vulnerabilities of PPM1D-mutant gliomas | 000 | 3 | NIH | 2/1/2023 | $395,535 |
| | 2023 | 2023 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | U24CA237617 | Developing Informatics Technologies to Model Cancer Gene Regulation | 000 | 5 | NIH | 2/9/2023 | $718,986 |
| | 2023 | 2023 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | K08CA248727 | Investigating Transcriptional Elongation and Nuclear RNA Surveillance in Melanoma | 000 | 4 | NIH | 3/10/2023 | $195,902 |
| | 2023 | 2023 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | K00CA234842 | Investigating molecular mechanism of immune response during cancer progression | 001 | 6 | NIH | 11/21/2022 | $93,150 |
| | 2023 | 2023 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | UG1CA233180 | NCTN Lead Academic Participating Site at Dana-Farber/Partners Cancer Care | 000 | 5 | NIH | 2/28/2023 | $1,106,459 |
| | 2023 | 2023 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | R01CA237241 | Cancer-Specific Targeting and Function of Mammalian SWI/SNF (BAF) Chromatin Remodeling Complexes | 000 | 5 | NIH | 2/28/2023 | $395,669 |
| | 2023 | 2023 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | K08DK120930 | Integration of early genetic alterations and inflammation in gastroesophageal premalignancy | 000 | 5 | NIH | 1/27/2023 | $158,040 |
| | 2023 | 2023 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | F32CA254118 | Identifying Combination Therapies in Ovarian Tumors using High Throughput Dynamic BH3 Profiling | 000 | 3 | NIH | 11/28/2022 | $71,734 |
| | 2023 | 2023 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | R21AG080395 | Formation and function of pathologic stress granules containing RNA-Binding Protein SFPQ in tauopathy | 000 | 1 | NIH | 1/6/2023 | $222,500 |
| | 2023 | 2023 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | F32GM149115 | Evaluating the mechanism by which the DYNLL1-MRE11 complex regulates DNA end resection and genome stability. | 002 | 1 | NIH | 2/9/2023 | $1,906 |
| | 2023 | 2023 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | F32GM149115 | Evaluating the mechanism by which the DYNLL1-MRE11 complex regulates DNA end resection and genome stability. | 001 | 1 | NIH | 2/8/2023 | $0 |
| | 2023 | 2023 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | F32GM149115 | Evaluating the mechanism by which the DYNLL1-MRE11 complex regulates DNA end resection and genome stability. | 000 | 1 | NIH | 1/12/2023 | $67,174 |
| | 2023 | 2023 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | K01DK132455 | The Role of Mitochondrial TNAP in Adaptive Thermogenesis | 000 | 1 | NIH | 11/30/2022 | $129,001 |
| | 2023 | 2023 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | R21CA277316 | Combined bromodomain and CDK4/6 inhibition in NUT Carcinoma and other solid tumors | 000 | 1 | NIH | 1/30/2023 | $226,502 |
| | 2023 | 2023 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | R01CA276268 | Mechanisms of response and resistance to KRAS inhibition in pancreatic cancer | 000 | 1 | NIH | 12/22/2022 | $542,026 |
| | 2023 | 2023 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | U01AI165442 | Identification of Metabolic and Immune Deficits in the Aged Population and Their Restoration to Achieve Youthful Anti-Influenza Vaccine Responsiveness | 000 | 2 | NIH | 10/31/2022 | $1,176,696 |
| | 2023 | 2023 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | R01CA270040 | BOLSTER: Strengthening Patient and Caregiver Supports in Advanced Gynecologic and Gastrointestinal Cancers - a Multi-Site Randomized Controlled Trial | 000 | 1 | NIH | 1/27/2023 | $741,387 |
| | 2023 | 2023 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | K99HG012798 | Robust and cost-effective computational methods for haplotype-resolved genome assemblies | 000 | 1 | NIH | 2/13/2023 | $122,262 |
| | 2023 | 2023 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | R21CA267527 | Defining the impact of mutational drivers on the immune microenvironment of CLL | 001 | 2 | NIH | 1/27/2023 | $203,878 |
| | 2023 | 2023 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | R37CA269990 | Mechanisms by which LSD1 Promotes Neuroendocrine Differentiation and Small Cell Lung Cancer | 000 | 1 | NIH | 12/6/2022 | $463,135 |
| | 2023 | 2023 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | R01CA276156 | Mechanisms of natural killer cell resistance of treatment-persistent residual tumor cells in hematologic malignancies | 000 | 1 | NIH | 12/29/2022 | $406,038 |
| | 2023 | 2023 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | R37CA276044 | Liquid biopsy in myeloma to inform outcome and treatment decisions | 000 | 1 | NIH | 1/10/2023 | $407,175 |
| | 2023 | 2023 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | R21CA267138 | Targeting MUC1-C for the Treatment of Small Cell Lung Cancer Progression | 000 | 2 | NIH | 12/9/2022 | $187,996 |
| | 2023 | 2023 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | R21CA267138 | Targeting MUC1-C for the Treatment of Small Cell Lung Cancer Progression | 001 | 2 | NIH | 3/15/2023 | $16,711 |
| | 2023 | 2023 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | F32GM149085 | Characterization of LINE-1 reverse transcriptase activity | 001 | 1 | NIH | 2/10/2023 | $1,990 |
| | 2023 | 2023 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | R00EB030587 | Interrogating and rewiring cell signaling pathways in CAR-T cells with synthetic phosphotyrosine recognition domains | 000 | 4 | NIH | 1/31/2023 | $249,000 |
| | 2023 | 2023 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | R01CA238039 | Therapeutic Targeting of Immune Evasion from the MICA - NKG2D Pathway | 000 | 5 | NIH | 3/15/2023 | $510,440 |
| | 2023 | 2023 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | K08CA245209 | Enhancing Venetoclax Activity in Chemoresistant Acute Myeloid Leukemia | 000 | 4 | NIH | 3/1/2023 | $258,561 |
| | 2023 | 2023 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | R01DK117655 | Small molecules targeting hepatic glucose production and insulin resistance | 000 | 5 | NIH | 2/28/2023 | $650,222 |
| | 2023 | 2023 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | R01CA239660 | The Function of CDK5 in Metastasis | 000 | 5 | NIH | 2/27/2023 | $432,500 |
| | 2023 | 2023 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | R01CA201049 | Discovery and optimization of novel mutant-selective allosteric inhibitors of EGFR T790M | 001 | 8 | NIH | 3/16/2023 | $39,242 |
| | 2023 | 2023 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | R01CA201049 | Discovery and optimization of novel mutant-selective allosteric inhibitors of EGFR T790M | 000 | 8 | NIH | 12/16/2022 | $441,496 |
| | 2023 | 2023 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | R01CA240592 | Early change in plasma tumor DNA as a patient and trial-level diagnostic in advanced lung cancer | 000 | 4 | NIH | 3/14/2023 | $427,031 |
| | 2023 | 2023 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | R01CA236226 | Novel therapeutic approaches with CDK4/6 inhibitors for melanoma treatment | 000 | 5 | NIH | 11/16/2022 | $429,879 |
| | 2023 | 2023 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | R01CA259200 | Genomic Diversity of Prostate Cancer Across the African Diaspora | 000 | 2 | NIH | 1/27/2023 | $1,284,929 |
| | 2023 | 2023 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | R01CA236226 | Novel therapeutic approaches with CDK4/6 inhibitors for melanoma treatment | 001 | 5 | NIH | 3/15/2023 | $38,212 |
| | 2023 | 2023 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | K08CA259623 | Elucidating the impact of DNA hypomethylation on genome organization and anti-tumor transcriptional programs | 000 | 4 | NIH | 3/8/2023 | $195,134 |
| | 2023 | 2023 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | R01CA237066 | Targeting of tumor cell DHHC3 to enhance anti-cancer immunity | 000 | 4 | NIH | 2/23/2023 | $392,207 |
|
